Probiotix Health PLC - New Commercial Partnership in Australia
ProBiotix Health plc
("ProBiotix" or the "Company" or, together with its subsidiary, the "Group")
New Commercial Partnership in
ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, is pleased to announce a commercial partnership with
Wellizen is an innovation-driven wellness consumer brand company with a focus on health solutions in nutrition, microbiome and lifestyle wellness. Headquartered in
ProBiotix will supply LPLDL® for local manufacturing of a new innovative dietary supplement capsule product targeting cardiometabolic health: Tri-Biotic Cardi-Flo, introduced under the THERONOMIC® brand. The commercial rollout will take place in October this year, with an initial launch in
The nutraceutical segment addressing cardiometabolic health is experiencing strong growth across all the target regions, with market expansion rates of 8-10% annually*, driven by rising lifestyle-related health concerns and demand for clinically supported, science-based preventive product solutions.
"High cholesterol affects an estimated 30-48% of adults in
"This product showcases our innovative Tribiotic® platform and features LPLDL®, a clinically studied probiotic strain with proven benefits for cardiometabolic health. Our partnership with ProBiotix reflects a shared commitment to advancing microbiome science, and we are confident Cardi-Flo will bring meaningful impact to consumers seeking natural, evidence-based support for heart health."
*Source: Precedence Research - Asia Pacific Cardiovascular Health Supplements Market (2025-2034), Grand View Research - Asia Pacific Cardiovascular Health Supplements Market Size & Outlook (2025-2030)
**Source: Prevalence of plasma lipid disorders with an emphasis on LDL cholesterol in selected countries in the
For further information, please contact:
|
ProBiotix Health plc |
|
|
|
|
|
|
|
|
|
|
|
Peterhouse Capital Limited Aquis Corporate Adviser and Broker |
|
|
|
Tel: 020 7469 0930 |
|
|
|
This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the
Notes to Editors:
ProBiotix is a life sciences company that develops probiotic formulations to support cardiometabolic health. Since its formation, ProBiotix has become recognised as a global leader in microbiome modulating probiotics for use in food supplements and nutraceuticals.
The Company has a singular approach: discovering ground breaking probiotics, ensuring their benefits through robust science, and bringing to market effective finished probiotic-based products for human health across the globe.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE